The purpose of this study is to provide subjects who participated in prior studies of EXC 001 the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: Week 2 to Week 24
Number of Participants With Positive Skin Sensitivity Reaction
Timeframe: Day 1 up to Week 24
Number of Participants With Clinically Significant Findings in Laboratory Examinations
Timeframe: Day 1 up to Week 24
Number of Participants With Clinically Significant Change in Vital Signs
Timeframe: Day 1 up to Week 24
Number of Participants With Clinically Significant Findings in Electrocardiogram (ECG) Abnormalities
Timeframe: Day 1 up to Week 24
Number of Participants With Abnormalities in Physical Examinations
Timeframe: Day 1 up to Week 24